Anne‐Marie C. Dingemans

Assessing the Operational Feasibility of Evolutionary Therapy in Metastatic Non-Small Cell Lung Cancer

Evolutionary cancer therapy (ECT) applies principles of evolutionary game theory to prolong the effectiveness of cancer treatment by curbing the development of treatment resistance. It was shown to increase time to progression while decreasing the cumulative drug dose. ECT indivi...

Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer

BackgroundPatients with extensive-stage small-cell lung cancer have poor outcomes, with a median overall survival of approximately 12 to 13 months. Tarlatamab (a bispecific T-cell engager targeting delta-like ligand 3 [DLL3] and CD3) was previously shown to improve survival as se...

Deep molecular profiling of lung neuroendocrine tumours and supra-carcinoids

BACKGROUND: Lung neuroendocrine tumours (NETs, also known as carcinoids) are rapidly rising in incidence worldwide but have unknown aetiology and limited therapeutic options beyond surgery. The current WHO classification, based on mitotic count and presence or absence of necrosis...